tbuckley/cabot-search huggingface dataset:
Clinical outcome of permanent prostate brachytherapy for low-, intermediate-, and high-risk cases.
Authors: Yasuto Yagi, Ken Nakamura, Choichiro Ozu, Toru Nishiyama, Kazuhito Toya, Atsunori Yorozu, Shiro Saito
Journal: Journal of Clinical Oncology (2014)

e16052 Background: This study is to evaluate long-term outcomes of prostate brachytherapy (BT) with I-125 permanent seed implantation. Methods: Between September 2003 and September 2008, 1054 patients underwent BT for cT1-3N0M0 prostate cancer at single institution. Among those patients, 1036 were able to be followed for more than 5 years. Kaplan-Meier analysis was performed to evaluate their overall survival rate (OS), disease-specific survival rate (DSS), clinical progression-free survival rate (CPFS) and biochemical progression-free survival rate (BPFS). The Phoenix definition was used to determine biochemical failure after the treatment. However, clear prostate-specific antigen (PSA) bounce cases were excluded from failure for the analysis. Univariate and multivariate regression analysis were performed by log-rank test and Cox’s proportional hazard regression model, respectively. Toxicity was scored by the Common Terminology Criteria for Adverse Events v.4.0. Results: The median follow-up period was 6.9 years.The OS, DSS, CPFS and BPFS at 10-year were 89.8%, 99.5%, 92.1% and 90.7%, respectively. Of 1036 patients, 358 (34.5%) were low risk cases, 578 (55.8%) were intermediate risk cases and 100 (9.7%) were high risk cases. BPFS of each risk classification was 98.2%, 87.8% and 78.6% at 10-year in the order of low, intermediate and high risk. The significant features of BPFS were initial PSA, Gleason score, clinical stage, positive biopsy core rate on biopsy, external beam radiotherapy and Biologically Effective Dose by the log-rank test. Initial PSA, Gleason Score and clinical stage were identified as independent predictors of PSA recurrence after BT by multivariate Cox proportional hazards survival analysis.Genitourinary and gastrointestinal toxicities of Grade 3 or more were 1.4% and 0.4% respectively. Conclusions: Analysis for long-term outcomes of BT for prostate cancer revealed excellent results. BT can be considered as a treatment option not only for low risk cases but also for intermediate and high risk cases.
EFFECTS OF DIABETES MELLITUS ON CLINICAL OUTCOMES AFTER LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION: A SINGLE INSTITUTIONAL 9-YEAR EXPERIENCE
Authors: Rabea Asleh, Sarah Schettle, Alexandros Briasoulis, Vakhtang Tchantchaleishvili, Naveen Pereira, Brooks Edwards, Alfredo Clavell, Simon Maltais, David L. Joyce, Soon Park, Lyle Joyce, Richard Daly, Sudhir Kushwaha, John Stulak
Journal: Journal of the American College of Cardiology (2017)
Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial–Mesenchymal Plasticity in Prostate Cancer
Authors: Lu Miao, Lin Yang, Rui Li, Daniel N. Rodrigues, Mateus Crespo, Jer-Tsong Hsieh, Wayne D. Tilley, Johann de Bono, Luke A. Selth, Ganesh V. Raj
Journal: Cancer Research (2017)

Epithelial-to-mesenchymal plasticity (EMP) has been linked to metastasis, stemness, and drug resistance. In prostate cancer, EMP has been associated with both suppression and activation of the androgen receptor (AR) signaling. Here we investigated the effect of the potent AR antagonist enzalutamide on EMP in multiple preclinical models of prostate cancer and patient tissues. Enzalutamide treatment significantly enhanced the expression of EMP drivers (ZEB1, ZEB2, Snail, Twist, and FOXC2) and mesenchymal markers (N-cadherin, fibronectin, and vimentin) in prostate cancer cells, enhanced prostate cancer cell migration, and induced prostate cancer transformation to a spindle, fibroblast-like morphology. Enzalutamide-induced EMP required concomitant suppression of AR signaling and activation of the EMP-promoting transcription factor Snail, as evidenced by both knockdown and overexpression studies. Supporting these findings, AR signaling and Snail expression were inversely correlated in C4-2 xenografts, patient-derived castration-resistant metastases, and clinical samples. For the first time, we elucidate a mechanism explaining the inverse relationship between AR and Snail. Specifically, we found that AR directly repressed SNAI1 gene expression by binding to specific AR-responsive elements within the SNAI1 promoter. Collectively, our findings demonstrate that de-repression of Snail and induction of EMP is an adaptive response to enzalutamide with implications for therapy resistance. Cancer Res; 77(11); 3101-12. ©2017 AACR.
INFLAMMATORY RESPONSE TO MENTAL STRESS AND MENTAL STRESS INDUCED MYOCARDIAL ISCHEMIA
Authors: Muhammad Hammadah, Brad Pearce, Naser Abdelhadi, Mazen Ghafeer, Ayman Alkhoder, Malik Obideen, Oleksiy Levantsevych, Lie Weng, Ibhar Al Mheid, Kobina Wilmot, Ronnie Ramadan, Heval Mohamed Kelli, Wesley O'Neal, Ayman Samman Tahhan, Pratik Pimple, Samaah Sulivan, Pratik Sandesara, Amit Shah, Yan Sun, Doug Bremner, Raggi Paolo, Viola Vaccarino, Arshed Quyyumi
Journal: Journal of the American College of Cardiology (2017)
RENALGUARD SYSTEM FOR THE PREVENTION OF CONTRAST-INDUCED NEPHROPATHY IN PATIENTS AT HIGH AND VERY-HIGH RISK UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION
Authors: Rocío González Ferreiro, Diego Lopez Otero, Ramiro Trillo Nouche, Diego Alvarez Iglesias, Adrian Cid Menendez, Leyre Alvarez Rodriguez, Ana Belen Cid Alvarez, Juan Carlos Sanmartin Pena, Jose Ramon Gonzalez Juanatey
Journal: Journal of the American College of Cardiology (2017)
TOWARD IDENTIFYING PERSONALIZED PROGNOSIS IN HYPERTENSION: VARIATION IN EARLY RESPONSES IN THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT)
Authors: Sanket Shishir Dhruva, Chenxi Huang, Erica Spatz, Andreas Coppi, Frederick Warner, Shu-Xia Li, Haiqun Lin, Xiao Xu, Curt Furberg, Barry Davis, Sara Pressel, Ronald Coifman, Harlan Krumholz
Journal: Journal of the American College of Cardiology (2017)
Multicellular Biohybrid Materials: Probing the Interplay of Cells of Different Types Precisely Positioned and Constrained on 3D Wireframe‐Like Microstructures
Authors: Maurizio R. Gullo, Shoji Takeuchi, Oliver Paul
Journal: Advanced Healthcare Materials (2017)

Driven by the unbroken miniaturization trend in microtechnology, the development of smaller, yet reliable and efficient, highly integrated microsystems can benefit from inherent capabilities of biological cells. In particular, by featuring multiple types of cells, biohybrid systems exhibiting self-contained sensing and actuation capabilities can be conceived. To ensure the proper functioning of such multicellular biohybrid systems, the intended cell arrangement needs to be maintained over time. Microscaffolds designed for this purpose should therefore selectively guide or hinder cell migration. However, the basic cell-structure interactions governing the cell migration and extension processes are not yet fully understood. This paper explores these interactions and proposes a method for the fabrication of advanced multicellular biohybrid materials. The method is based on wireframe-like 3D microstructures onto which several types of cells are successfully positioned and arranged by optical manipulation. Experiments exploring cell dynamics reveal geometry-dependent maximal migration and extension distances. Microscaffolds designed on the basis of these characteristics can guide cell migration, trigger structure-contained cell growth, and maintain a predetermined cell arrangement. The methods reported herein therefore provide insight into cell assembly and migration on 3D microscaffolds, which is an essential early step towards advanced multicellular biohybrid materials.
Clinical and prognostic significance of serum carcinoembryonic antigen level in patients with IIIB and IV stage lung cancer: A prospective study
Authors: A. Martinez-Velazco, D. Flores-Estrada, J. C. Silva-Godinez, F. Javier, G. Enrique, L. Martinez, J. De la Garza, O. Arrieta
Journal: Journal of Clinical Oncology (2007)

18063 Previous studies have shown pre and post-operative serum CEA levels are a prognostic factor in patients with lung cancer (LC). We prospectively investigated the clinical and pathological characteristics, as well as, prognostic significance of patients with IIIB and IV stage LC and the CEA serum elevation. From March of 2005 to January of 2007, 307 patients with IIIB and IV stage were included; several chemotherapy protocols including gemcitabine, vinorelbine or paclitaxel combined with cisplatin, carboplatin, or erlotinib were used. Serum CEA levels were obtained before and after 2 cycles of treatment. Stage was determined by CT and bone scans; 120 patients had brain CT scan at diagnosis due to neurological symptoms. 28.6% of the patients were stage IIIB and 61.4% stage IV and 18% of patients had CNS metastasis at diagnosis. Histology was adenocarcinoma in 69.1% and epidermoid in 30.9%. Mean CEA was 11.3 ng/ml ± 24.5 with median of 6.7 (range 0.2 to 4,578). Patients with CEA levels &gt; 10, 20, 50 and 100 were 43.6, 32.5, 24 and 17.9%; respectively. Associated factors with CEA &gt;20 were age &gt;62 (p=0.02), stage (p=0.05), CNS metastasis (p=0.0001) and histology (p=0.01). However, in the logistic regression analysis the only associated factors were histology (p=0.0001) and CNS metastasis (p=0.0001). Patients with CEA elevation &gt;20 had a hazard ratio of 26.3 (CI 11.2 to 61.6) for the development of brain metastases. Overall survival associated factors were poor status performance (p=0.006), tobacco use (p=0.05), CEA elevation (p=0.0022), CNS metastases (p=0.01), male gender (p=0.08). There were no differences between stage IIIB, IV and CNS metastasis. The associated factors with survival by Cox proportional hazards regression multivariate analysis were poor performance status (p=0.05) and CEA elevation (p=0.008). The independent factors associated with CEA elevation were histology adenocarcinoma and brain metastasis. Patients with CEA &gt;20 without neurological symptoms could benefit from early CT brain scan with stage IIIB and IV. In this group of patients, the 2 most important independent factors for survival were poor performance status and CEA elevation. No significant financial relationships to disclose.
HEART FAILURE HOSPITALIZATION (HFH) DESPITE DIGOXIN THERAPY VERSUS NO HFH DESPITE PLACEBO IN THE DIGITALIS INVESTIGATION GROUP (DIG) TRIAL: INSIGHTS INTO RISK FACTORS FOR HFH IN HF AND REDUCED EJECTION FRACTION (HFREF)
Authors: Poonam Bhyan, Apostolos Tsimploulis, Daniel Dooley, Phillip Lam, Cherinne Arundel, Prakash C. Deedwania, Gregg Fonarow, Javed Butler, Michelle White, Wen-Chih Wu, Wilbert Aronow, Ioannis Kanonidis, Charity Morgan, Bertram Pitt, Marc Blackman, Deepak Bhatt, Aliy Ahmed
Journal: Journal of the American College of Cardiology (2017)
THE FUNCTIONAL RELEVANCE OF HIGH DENSITY LIPOPROTEIN STRUCTURE AND COMPOSITION IN THE IMPROVEMENT OF CHOLESTEROL EFFLUX CAPACITY AFTER ROUX-EN-Y GASTRIC BYPASS
Authors: Elena Osto, Petia Doytcheva, Jeremy Deuel, Dominik Schaer, Thomas Lutz, Thomas F. Luscher
Journal: Journal of the American College of Cardiology (2017)
OUTCOMES OF PRE-LOADING VS IN-LAB LOADING WITH PRASUGREL AND TICAGRELOR IN PATIENTS WITH ACUTE CORONARY SYNDROMES (ACS) UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
Authors: Prasanna Venkataraman, Nick Andrianopoulos, Andrew Teh, Louise Roberts, Stephen Duffy, Angela Brennan, Andrew Ajani, David Clark, Martin Sebastian, Christopher Reid, Melanie Freeman
Journal: Journal of the American College of Cardiology (2017)
CIRCULATING FREE AND EXOSOMAL MICRORNAS AS BIOMARKERS OF SYSTEMIC RESPONSE TO HEART FAILURE
Authors: Faheemullah Beg, Ruizhong Wang, Zeb Saeed, Srikant Devaraj, Masoor Kamalesh, Harikrishna Nakshatri, Richard L. Roudebush
Journal: Journal of the American College of Cardiology (2017)
IN-HOSPITAL OUTCOMES AFTER MITRACLIP IMPLANTATION IN THE UNITED STATES: 2010-2012
Authors: Sagar Mallikethi-Reddy, Naveen Trehan, Shanker Kundumadam, Tesfaye Telila, Anupama Kottam, Shaun Cardozo, Melvyn Rubenfire, Luis Afonso, Cindy Grines
Journal: Journal of the American College of Cardiology (2017)
LONG-TERM PATHOLOGICAL RESULT OF EVEROLIMUS-ELUTING STENT VERSUS SILOLIMUS-ELUTING STENT AND BARE METAL STENT
Authors: Hiroyoshi Mori, Dheeraj Atmakuri, Robert Kutys, Ryan Braumann, Sho Torii, Maria Romero, Emanuel Harari, Renu Virmani, Aloke Finn
Journal: Journal of the American College of Cardiology (2017)
Effect of everolimus on angiogenic biomarkers in patients with tuberous sclerosis complex (TSC)
Authors: David Neal Franz, Christopher Kingswood, Sergiusz Jozwiak, Klemens Budde, Elena Belousova, Steven Sparagana, B. A. Zonnenberg, Michael Frost, Gaurav D. Shah, Jeremie Lebrec, James Ford, Creton Kalfoglou, David Chen, John Bissler
Journal: Journal of Clinical Oncology (2012)
TARGETED AND EXOME SEQUENCING OF 27 LEBANESE PATIENTS WITH CARDIOMYOPATHIES: NOVEL VARIANTS IN KNOWN GENES, AND POTENTIAL NOVEL GENES
Authors: Marwan Refaat, Sylvana Hassanieh, Patrick Zakka, Mostafa Hotait, Jad Ballout, Fadi Bitar, Mariam Arabi, M. Samir Arnaout, Hadi Skouri, Antoine Abchee, Hussain Ismaeel, Bernard Abi-Saleh, Maurice Khoury, Georges Nemer
Journal: Journal of the American College of Cardiology (2017)
TRENDS AND OUTCOMES OF PERMANENT PACEMAKER IMPLANTATION AFTER MITRAL VALVE REPLACEMENT: A 10 YEAR U.S. ANALYSIS
Authors: Fahad Alqahtani, Sami Aljohani, Ahmed Almustafa, Ashwin Bhirud, Stanley Schmidt, Mohamad Alkhouli
Journal: Journal of the American College of Cardiology (2017)
FLT3, CD32, PU.1, ERG, uPAR, and TAP2 Are Strongly Associated with the Progression of Chronic Myeloid Leukemia and Combination of Small Interference RNA of FLT3 and STI571 Synergistically Induced Apoptosis of K562 Cells
Authors: Kyung Im Kim, Kwang-Sung Ahn, Juwon Park, Chansu Lee, Byoung Kook Kim, Young-Yiul Lee, Jung Mi Oh, Sung-Soo Yoon
Journal: Blood (2008)
IMPACT OF HEREDITARY CAUSES OF THROMBOSIS ON ACUTE MYOCARDIAL INFARCTION BETWEEN THE YEARS 2008 THROUGH 2012: NATIONWIDE INPATIENT SAMPLE DATA ANALYSIS
Authors: Yashwant Agrawal, Chris Jacob, Carleigh Zahn, Sourabh Aggarwal, Sidakpal Panaich, Frank Saltiel, Jagadeesh Kalavakunta, Vishal Gupta
Journal: Journal of the American College of Cardiology (2017)
GBM cell microvesicles carrying gDNA oncogenic sequences cross the BBB and reach the peripheral blood.
Authors: Esther Holgado, Noemi Garcia-Romero, Josefa Carrion-Navarro, Elisa Lazaro-Ibanez, Carmen Escobedo, Cristina Gonzalez Perez, Pilar Sanhez, Marta Alonso, Lorea Materola, Ricardo Prat, Cristobal Belda-Iniesta, Angel Ayuso-Sacido
Journal: Journal of Clinical Oncology (2014)

11073 Background: Glioblastoma (GBM) is the most common primary malignant brain tumor in adults accounting for 60-75% of astrocytic tumors. It corresponds to WHO grade IV. Microvesicles (MVs) are vesicles that can be found in body fluids from patients with different types of cancer. These MV can be classified into apoptotic breakdown (up to several µm), plasma membrane blebbing (100 to 1,000 nm), and exosomes (less than 100 nm) released by fusion of endosomal-derived multivesicular bodies They play a crucial role in tumor progression since they can mediate intercellular communication, inflammation, angiogenesis and coagulation. We have identified, for the first time, the presence of genomic DNA sequences corresponding to oncogenes from all three types of MVs. These three types of MVs can cross the bbb and reach the peripheral blood where gDNA sequences might be used as biomarkers to stratify patients and evaluate response to treatment. Methods: GBM-initiating cells were isolated from surgical samples and cultured. A collection of primers targeting specifically human gDNA were designed and validated. Using a modification of the protocol proposed by Skog group we isolated apoptotic, blebbing, and exosomes. Afterwards, we isolated total gDNA from supernatant of cells and mice plasma with brain tumor. This gDNA was used as a template for de detection of gDNA oncogene sequences. Finally, we confirmed the presence of such sequences within all three type of MVs isolated from peripheral blood of GBM patients. Results: We found gDNA oncogene sequences within all three types of MVs. We demonstrated that MVs secreted by tumor cells into the brain can cross the bbb and reach the peripheral blood, were they contribute to the total number of circulating MVs y mice model. gDNA oncogenic sequences can be also detected in all three types of MVs isolated from peripheral blood of GBM patients. Conclusions: gDNA sequences can be introduced into apoptotic and blebbing MVs, and exosomes. These three types of MVs can cross the bbb and reach the peripheral blood where they can be detected by using low invasive procedures. The presence of gDNA will be useful for the detection of specific mutations, and/or epigenetic changes in the producer tumor cell.
Locally advanced rectal cancer: The value of magnetic resonance imaging as a predictive tool.
Authors: Louise Catherine Connell, Charlotte Stuart, Norma Daly, Brian Mehigan, M. John Kennedy
Journal: Journal of Clinical Oncology (2013)

e14666 Background: Magnetic Resonance Imaging (MRI) of pelvis stratifies patients (pts) with rectal cancer (ca) according to locally advanced disease (dx) &amp; risk of local recurrence. By determining the extent of lymph node (LN) positivity, it enables the appropriate selection of pts for neoadjuvant therapy (NAT) prior to curative surgical resection (Sx). We assessed our institution’s experience of NAT versus upfront Sx in stage I-III rectal ca to ascertain the utility of MRI as a predictive tool in LN status evaluation. Methods: We retrospectively reviewed a prospectively maintained database for all pts with a diagnosis of stage I-III rectal ca from January 2006 to September 2012 in a specialist colorectal cancer centre. We analysed data with respect to preoperative MRI staging &amp; definitive histopathological confirmation of LN stage. Results: A total of 210 pts were identified that had Sx for rectal ca with curative intent. Of these, 112 pts received NAT while 98 had upfront Sx. Of those who proceeded directly to Sx, there were 41 females &amp; 57 males. Average age in this group was 73.4 years (range 33 -90). LN staging by MRI was accurate in 45.9% (n=45). LN status could not be evaluated (Nx) in 17.3% (n=17). In 19.4% (n=19) more advanced LN staging was apparent on histology while in 17.3% (n=17) LN stage was deemed more aggressive by MRI. Of those who had NAT, there were 75 males &amp; 37 females. Average age was 62.3 years (range 26-82). In this cohort, 81.3% (n=91) had both a preoperative MRI &amp; pathology report available for comparison. MRI in this group matched histology in 61.5% (n=56). Nx was recorded in 3.3 % (n=3). In 17.6% (n=16) more aggressive LN involvement was evident at histology while 17.6% (n= 16) had less advanced dx at tissue sampling. Overall in this study, MRI accurately predicted LN status in 53.4% (n=101). Conclusions: While MRI is a valuable tool in determining those pts with rectal ca that would benefit from NAT, its predictive value has limitations. With further analysis of the dataset at our institution, we aim to identify other factors involved &amp; create a predictive nomogram for the rectal ca pt with locally advanced dx. We plan to validate this work by including data from other Irish cancer centres.
The impact of induction chemotherapy on subsequent concurrent chemoradiotherapy (CRT) related side effects, function &amp; quality of life (QOL) in head and neck cancer (HNC)
Authors: M. A. List, D. Haraf, R. Egan, P. Bilir, K. Stenson, T. Karrison, E. E. Vokes
Journal: Journal of Clinical Oncology (2004)

5537 Background: The role of chemotherapy in the treatment of advanced HNC continues to evolve. Concurrent CRT has been shown to improve locoregional control and overall survival, while induction chemotherapy has demonstrated efficacy in decreasing distant metastases. The acute toxicity of adding chemotherapy, however, remains a concern. This paper examines functional/QOL parameters and the impact of adding induction chemotherapy to CRT regimens. Methods: Standardized measures of performance (PSS-HN), QOL (FACT-H&N) and patient-rated side effects were administered to 179 patients treated on one of five sequential CRT trials at University of Chicago. Trials 1 & 2 (Group A) included five cycles of twice daily radiation with concurrent CRT (5-FU, hydroxyurea, paclitaxel). Trials 3, 4 & 5 (Group B) added two cycles of induction chemotherapy (carboplatin, paclitaxel). Results: Pre and on-treatment data are available on 41/49 Group A patients and 94/130 Group B patients. Between group differences in change from baseline were examined separately by item or subscale. First, a series of t-tests was used to examine mean differences. No statistically significant differences were found. Secondly, difference in change was assessed by dichotomizing patient outcomes into worse (≥ 2 point decline on 1–7 side effect scales; ≥ 20 point decline on PSS-HN 10–100 Diet scale) vs. same or better. By chi square analyses, the only significant difference was horseness, for which 61% of Group B patients reported more problems vs. 40% of Group A (p=.03). There was a trend for Group B to report a greater increase in mouth pain (56% vs 40%, p=.09). Conclusions: These findings suggest that, on average, at least for the current regimen, induction chemotherapy does not increase patients' side effects nor decrease QOL beyond that of CRT alone; nor does it substantially increase the percent of patients whose symptoms worsen during CRT. Given the recently renewed interest in the role of induction chemotherapy these results are encouraging but should be confirmed in larger randomized trials and with other induction regimens. No significant financial relationships to disclose.
INCIDENCE OF ACUTE KIDNEY INJURY WITH BIVALIRUDIN OR UNFRACTIONATED HEPARIN FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT: RESULTS FROM THE BRAVO-3 RANDOMIZED TRIAL
Authors: Jaya Chandrasekhar, Roxana Mehran, Christian Hengstenberg, Birgit Vogel, Anita Asgar, Jurrien Ten Berg, Ghada Mikhail, Nicolas Meneveau, Julian Widder, Roberto Violini, David Hildick-Smith, Peter Boekstegers, Van Belle Eric, Oliver Husser, Hans Ulrich Hink, Peter Wijngaard, Eberhard Grube, Usman Baber, Efthymios Deliargyris, Prodromos Anthopoulos, George Dangas
Journal: Journal of the American College of Cardiology (2017)